Medicenna Therapeutics Corp. (MDNAF)
OTCMKTS · Delayed Price · Currency is USD
0.6100
-0.0040 (-0.65%)
Jul 24, 2025, 4:00 PM EDT
Medicenna Therapeutics Employees
Medicenna Therapeutics had 18 employees as of March 31, 2025. The number of employees increased by 2 or 12.50% compared to the previous year.
Employees
18
Change (1Y)
2
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$456,280
Market Cap
51.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 18 | 2 | 12.50% |
| Mar 31, 2024 | 16 | 0 | - |
| Mar 31, 2023 | 16 | -2 | -11.11% |
| Mar 31, 2022 | 18 | 5 | 38.46% |
| Mar 31, 2021 | 13 | 6 | 85.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
Medicenna Therapeutics News
- 4 weeks ago - Medicenna Therapeutics GAAP EPS of -C$0.15 - Seeking Alpha
- 4 weeks ago - Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 4 months ago - Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 5 months ago - Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones - GlobeNewsWire
- 6 months ago - Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025 - GlobeNewsWire
- 8 months ago - Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 8 months ago - Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study - GlobeNewsWire
- 8 months ago - Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference - GlobeNewsWire